Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Bajetta, M. Bartolomeo, R. Buzzoni, L. Mariani, N. Zilembo, E. Ferrario, S. Vullo, E. Aitini, L. Isa, C. Barone, S. Jacobelli, E. Recaldin, G. Pinotti, A. Iop (2007)Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study
British Journal of Cancer, 96
KyungMann Kim, S. Thompson (2012)Contrasting treatment‐specific survival using double‐robust estimators
F. Molinari, L. Felicioni, M. Buscarino, S. Dosso, F. Buttitta, S. Malatesta, A. Movilia, M. Luoni, R. Boldorini, O. Alabiso, S. Girlando, B. Soini, A. Spitale, F. Nicolantonio, P. Saletti, S. Crippa, L. Mazzucchelli, A. Marchetti, A. Bardelli, M. Frattini (2011)Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer
Clinical Cancer Research, 17
W. Roock, B. Claes, D. Bernasconi, J. Schutter, B. Biesmans, G. Fountzilas, K. Kalogeras, V. Kotoula, D. Papamichael, P. Laurent-Puig, F. Penault-Llorca, P. Rougier, B. Vincenzi, D. Santini, G. Tonini, F. Cappuzzo, M. Frattini, F. Molinari, P. Saletti, S. Dosso, M. Martini, A. Bardelli, S. Siena, A. Sartore-Bianchi, J. Tabernero, T. Macarulla, F. Fioré, A. Gangloff, F. Ciardiello, P. Pfeiffer, C. Qvortrup, T. Hansen, E. Cutsem, H. Piessevaux, D. Lambrechts, M. Delorenzi, S. Tejpar (2010)Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
The Lancet. Oncology, 11 8
C. Karapetis, S. Khambata-Ford, D. Jonker, C. O'Callaghan, D. Tu, N. Tebbutt, R. Simes, H. Chalchal, J. Shapiro, S. Robitaille, T. Price, L. Shepherd, H. Au, C. Langer, M. Moore, J. Zalcberg (2008)K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
The New England journal of medicine, 359 17
F. Perrone, P. Bossi, B. Cortelazzi, L. Locati, P. Quattrone, M. Pierotti, S. Pilotti, L. Licitra (2010)TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 5
Cornelis Punt (2004)New options and old dilemmas in the treatment of patients with advanced colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology, 15 10
P Therasse, SG Arbuck, EA Eisenhauer, J Wanders, RS Kaplan, L Rubinstein, J Verweij, M Glabbeke, AT Oosterom, MC Christian, SG Gwyther (2000)New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
J Natl Cancer Inst, 92
K. Tveit, T. Guren, B. Glimelius, P. Pfeiffer, H. Sorbye, S. Pyrhonen, F. Sigurdsson, E. Kure, T. Ikdahl, E. Skovlund, T. Fokstuen, F. Hansen, E. Hofsli, Elke Birkemeyer, A. Johnsson, H. Starkhammar, M. Yilmaz, N. Keldsen, Anne Erdal, O. Dajani, O. Dahl, T. Christoffersen (2012)Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 15
T. Maughan, R. Adams, Christopher Smith, A. Meade, M. Seymour, R. Wilson, S. Idziaszczyk, Rebecca Harris, D. Fisher, S. Kenny, E. Kay, J. Mitchell, A. Madi, B. Jasani, M. James, J. Bridgewater, M. Kennedy, B. Claes, D. Lambrechts, R. Kaplan, J. Cheadle (2011)Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
The Lancet, 377
N. Moosmann, L. Weikersthal, U. Vehling‐Kaiser, M. Stauch, H. Hass, H. Dietzfelbinger, D. Oruzio, S. Klein, K. Zellmann, T. Decker, M. Schulze, W. Abenhardt, G. Puchtler, H. Kappauf, J. Mittermüller, C. Haberl, A. Schalhorn, A. Jung, S. Stintzing, V. Heinemann (2011)Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 8
E. Cutsem, C. Köhne, E. Hitre, J. Zaluski, Chung-Rong Chien, A. Makhson, G. D'Haens, T. Pintér, R. Lim, G. Bodoky, J. Roh, G. Folprecht, P. Ruff, C. Stroh, S. Tejpar, M. Schlichting, J. Nippgen, P. Rougier (2009)Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
The New England journal of medicine, 360 14
F. Nicolantonio, M. Martini, F. Molinari, A. Sartore-Bianchi, S. Arena, P. Saletti, S. Dosso, L. Mazzucchelli, M. Frattini, S. Siena, A. Bardelli (2008)Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 35
E. Kaplan, P. Meier (1958)Nonparametric Estimation from Incomplete Observations
Journal of the American Statistical Association, 53
A. Jemal, R. Siegel, Elizabeth Ward, Y. Hao, Jiaquan Xu, M. Thun (2009)Cancer Statistics, 2009
CA: A Cancer Journal for Clinicians, 59
M. Prewett, A. Hooper, Rajiv Bassi, L. Ellis, H. Waksal, D. Hicklin (2002)Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research, 8 5
J. Benhattar, J. Cerottini, E. Saraga, G. Metthez, J. Givel (1996)p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas
International Journal of Cancer, 69
T. Yokota, T. Ura, N. Shibata, D. Takahari, K. Shitara, M. Nomura, C. Kondo, A. Mizota, S. Utsunomiya, K. Muro, Y. Yatabe (2011)BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
British Journal of Cancer, 104
B. Tran, S. Kopetz, J. Tie, P. Gibbs, Zhi-qin Jiang, C. Lieu, A. Agarwal, D. Maru, O. Sieber, J. Desai (2011)Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
S. Kato, Shuang-yin Han, Wen Liu, Kazunori Otsuka, H. Shibata, R. Kanamaru, C. Ishioka (2003)Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis
Proceedings of the National Academy of Sciences of the United States of America, 100
S Kato, SY Han, W Liu, K Otsuka, H Shibata, R Kanamaru, C Ishioka (2003)Understanding the function?structure and function?mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis
Proc Natl Acad Sci U S A, 100
C. Bokemeyer, I. Bondarenko, J. Hartmann, F. Braud, G. Schuch, A. Zubel, I. Celik, M. Schlichting, P. Koralewski (2011)Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
Annals of oncology : official journal of the European Society for Medical Oncology, 22 7
J. Douillard, P. Hoff, J. Skillings, P. Eisenberg, N. Davidson, P. Harper, M. Vincent, B. Lembersky, S. Thompson, A. Maniero, S. Benner (2002)Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 17
A Jemal, R Siegel, E Ward, Y Hao, J Xu, MJ Thun (2009)Cancer statistics
CA Cancer J Clin, 59
J. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. Burkes, M. Barugel, Y. Humblet, G. Bodoky, D. Cunningham, J. Jassem, F. Rivera, I. Kocáková, P. Ruff, M. Błasińska-Morawiec, M. Šmakal, J. Canon, M. Rother, K. Oliner, M. Wolf, J. Gansert (2010)Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 31
N. Smakman, D. Wollenberg, S. Elias, T. Sasazuki, S. Shirasawa, R. Hoeben, I. Rinkes, O. Kranenburg (2006)KRAS(D13) Promotes apoptosis of human colorectal tumor cells by ReovirusT3D and oxaliplatin but not by tumor necrosis factor-related apoptosis-inducing ligand.
Cancer research, 66 10
D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, D. Bets, M. Mueser, A. Harstrick, C. Verslype, I. Chau, E. Cutsem (2004)Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
The New England journal of medicine, 351 4
A. Grothey, D. Sargent, R. Goldberg, H. Schmoll (2004)Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 7
L. Klampfer, L. Swaby, Jie Huang, T. Sasazuki, S. Shirasawa, L. Augenlicht (2005)Oncogenic Ras increases sensitivity of colon cancer cells to 5-FU-induced apoptosis
F. Perrone, A. Lampis, M. Orsenigo, M. Bartolomeo, A. Gevorgyan, M. Losa, M. Frattini, C. Riva, S. Andreola, E. Bajetta, L. Bertario, E. Leo, M. Pierotti, S. Pilotti (2009)PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology, 20 1
P. Therasse, S. Arbuck, E. Eisenhauer, J. Wanders, R. Kaplan, L. Rubinstein, J. Verweij, Martine Glabbeke, Allan Oosterom, M. Christian, S. Gwyther (2000)New guidelines to evaluate the response to treatment in solid tumors
Breast Cancer, 12
A. Oden-Gangloff, F. Fiore, F. Bibeau, A. Lamy, G. Bougeard, F. Charbonnier, F. Blanchard, D. Tougeron, M. Ychou, F. Boissiere, F. Pessot, J. Sabourin, J. Tuech, Pierre Michel, Thierry Frebourg (2009)TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
British Journal of Cancer, 100
MT Bruijn, Dae Raats, F. Hoogwater, WJ Houdt, K. Cameron, J. Medema, I. Rinkes, O. Kranenburg (2010)Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa
British Journal of Cancer, 102
S. Lowe, H. Ruley, T. Jacks, D. Housman (1993)p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
F. Fioré, A. Lamy, F. Blanchard, A. Oden-Gangloff, R. Sesboüé, J. Sabourin, T. Frebourg, P. Michel, P. Laurent-Puig (2011)TP53 mutations in irinotecan-refractory KRAS wt-BRAF wt metastatic colorectal cancer patients treated with cetuximab-based chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 4_suppl
C. Mao, Zuyao Yang, Xiaolin Hu, Qing Chen, Jingjing Tang (2012)PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Annals of oncology : official journal of the European Society for Medical Oncology, 23 6
F. Perrone, L. Riva, M. Orsenigo, M. Losa, G. Jocollé, Clara Millefanti, Elisa Pastore, A. Gronchi, M. Pierotti, S. Pilotti (2009)PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor.
Neuro-oncology, 11 6
A. Munro, S. Laín, D. Lane (2005)P53 abnormalities and outcomes in colorectal cancer: a systematic review
British Journal of Cancer, 92
J. Douillard, T. Zemełka, G. Fountzilas, C. Barone, M. Schlichting, J. Heighway, S. Eggleton, V. Srimuninnimit (2014)FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study.
Clinical colorectal cancer, 13 1
There is conflicting evidence on the predictive role of KRAS status when cetuximab is added to oxaliplatin-based regimens. This study investigated the impact of KRAS, NRAS, BRAF, PI3KCA and TP53 status on outcome of elderly metastatic colorectal cancer patients enrolled in TEGAFOX-E (cetuximab, oxaliplatin and oral uracil/ftorafur—UFT) phase II study. Twenty-eight patients were enrolled and all were evaluable for safety and activity. Twenty-three specimens were analysed for KRAS, BRAF, NRAS, PI3KCA and TP53 mutational status by means of polymerase chain reaction and correlated with objective response, progression-free survival and overall survival. An evident increase of response rate was noted in KRAS/NRAS wild-type cases (70 versus 33 %, P = 0.198). KRAS/NRAS wild-type status showed an independent association with a longer progression-free survival (44 versus 9 weeks, P = 0.009). Considering the combined assessment of BRAF, KRAS/NRAS and TP53, a trend towards an increase of response rate was noted in patients without mutations (83 versus 33 %, P = 0.063). Moreover, patients with all wild-type genes had significantly longer progression-free survival than patients with any mutation (48 versus 10 weeks, P = 0.007). As a single biomarker, only KRAS/NRAS proteins maintained an independent value for outcome prediction. Patients with KRAS/NRAS, BRAF and TP53 wild-type tumours could derive the maximal benefits from treatment with cetuximab, oxaliplatin and UFT.
Targeted Oncology – Springer Journals
Published: Jul 3, 2013
Access the full text.
Sign up today, get DeepDyve free for 14 days.